TL;DR: A March 2026 Mayer Brown client alert titled “Fundamental Research, National Security, and the Quiet Shift Facing Universities” warns that the long-standing fundamental research exclusion under US export control rules is coming under sustained policy pressure. That alert is legal-risk commentary, not a report of an enacted Commerce Department or Bureau of Industry and Security (BIS) rule change — a search of the Federal Register and BIS.gov found no 2026 final rule, proposed rule, or interim guidance amending the fundamental research exclusion itself (codified at 15 CFR 734.8 under the Export Administration Regulations). What has actually happened is a cluster of adjacent, real developments — a research security program mandate, a foreign-gift disclosure crackdown, a new biotechnology procurement law, and pending legislation — that collectively narrow the practical space around fundamental research even though the exclusion’s own text is unchanged. This piece separates what is confirmed from what is currently only a law firm’s forward-looking warning, and links to CASRAI’s existing coverage of each underlying development.
What the fundamental research exclusion actually does
Under the Export Administration Regulations (EAR), information that arises from or is intended for basic and applied research ordinarily published and shared broadly within the scientific community is treated as “fundamental research” and falls outside the definition of controlled “technology” for deemed-export purposes — provided the research isn’t subject to publication restrictions or access/dissemination controls tied to national security. This exclusion, along with the related public-domain and educational-information carve-outs, is what has historically let US universities run open, internationally collaborative labs without treating every foreign national on a research team as requiring a deemed export license. It sits alongside, and is analytically distinct from, ITAR’s parallel fundamental research treatment under the International Traffic in Arms Regulations. For the full mechanics of how institutions determine whether a project actually qualifies — and what disqualifies it, such as accepting a sponsor’s publication-restriction clause or receiving export-controlled equipment or technical data — see CASRAI’s guide to export control (EAR/ITAR) in international research collaboration.
What the Mayer Brown alert actually claims
The alert’s own argument is not that BIS has issued a new rule narrowing the exclusion’s text. It argues that a series of separate government actions, taken together, are shrinking the practical room the exclusion has traditionally provided for research involving elevated-risk collaborators or technology areas — particularly where China-linked collaboration or dual-use technology is involved — and that university counsel should treat this as an emerging risk trend rather than a settled, static compliance picture. That is a legal-alert framing of a trend, and CASRAI is reporting it as exactly that: attributed commentary, not a regulatory fact.
What is actually confirmed and already in effect
Four real, verifiable developments sit behind the “quiet shift” framing:
- NSPM-33 research security programs. Institutions receiving more than $50 million per year in federal science and engineering support must operate a formal research security program under NSPM-33 and OSTP’s July 2024 implementation guidance, with agency-specific certification deadlines rolling through 2025 and 2026. See CASRAI’s coverage of the real NSPM-33 deadline mechanics and DoD’s January 2026 memo.
- Section 117 foreign-gift enforcement. The State Department has joined Education Department enforcement of Section 117 foreign-gift and contract disclosure requirements, adding disclosure and audit pressure on university-foreign relationships that overlaps with, but is legally distinct from, export control. See CASRAI’s coverage of the State Department’s Section 117 enforcement partnership.
- The BIOSECURE Act. Enacted as Section 851 of the FY2026 National Defense Authorization Act (P.L. 119-60), signed into law in December 2025, this law restricts federal procurement of biotechnology equipment and services from designated “biotechnology companies of concern.” It is a procurement-restriction statute, not an amendment to the EAR’s fundamental research exclusion, but it is part of the same broader pattern of China-linked research restrictions the Mayer Brown alert points to.
- Malign foreign talent recruitment program restrictions. Federal funders, including NSF, have tightened 2025 award restrictions tied to researcher participation in foreign talent recruitment programs — a certification and disclosure requirement, again separate from export control licensing.
None of these four amend 15 CFR 734.8 or the parallel ITAR fundamental research provision. What they do is add layers of disclosure, certification, and procurement restriction around the same population of internationally collaborative, federally funded research the exclusion covers — which is the practical basis for describing the environment as tightening even without a formal rule change.
What is not yet confirmed
The alert also references proposed legislation that would bar federal funding for fundamental research collaboration with designated “covered entities,” including PRC-affiliated universities. CASRAI has not independently verified specific bill numbers or current legislative status for that proposal beyond the law firm’s own characterization, and treats it as unenacted and attributed to that source only. Research offices should not treat pending legislation as current compliance obligation; it becomes relevant only if and when enacted.
What research administrators should actually do with this
Given no primary-source rule change exists yet, the practical action isn’t to reassess fundamental-research determinations already made under 15 CFR 734.8 — it’s to track the adjacent, confirmed obligations above (research security program certification deadlines, Section 117 disclosure, malign foreign talent recruitment program certifications, and, for institutions handling biotechnology procurement, BIOSECURE Act sourcing restrictions) as a compliance set that now sits alongside, not inside, export control review. Export control officers and research security officers increasingly need to coordinate on the same underlying projects even though the legal bases for their reviews remain separate. Institutions that rely on outside counsel alerts like this one for early warning should treat them as exactly that — a signal to monitor Federal Register activity and BIS guidance more closely for the specific area flagged, not as notice that a rule has already changed.
Frequently asked questions
Has BIS actually changed the fundamental research exclusion?
Not as of this writing, based on a direct check of the Federal Register and BIS.gov. No 2026 final or proposed rule amending 15 CFR 734.8 was located. The “narrowing” described in the Mayer Brown alert is a characterization of surrounding policy pressure, not a report of a specific BIS rulemaking.
Does the BIOSECURE Act change export control law?
No. It is a federal procurement restriction (Section 851 of the FY2026 NDAA, P.L. 119-60) barring agencies and their contractors from sourcing biotechnology equipment or services from designated “biotechnology companies of concern.” It does not amend the EAR or ITAR fundamental research provisions.
What should a research office do differently right now?
Continue documenting fundamental-research determinations under existing EAR/ITAR criteria as before, while separately tracking the institution’s NSPM-33 certification deadline, Section 117 disclosure obligations, and any biotechnology procurement sourcing checks that now apply. These are parallel compliance tracks, not a replacement for export control review.
Where can I read the underlying alert?
The Mayer Brown client alert, “Fundamental Research, National Security, and the Quiet Shift Facing Universities” (March 2026), is publicly available on Mayer Brown’s website and was also syndicated via Mondaq. CASRAI is summarizing and fact-checking its framing here, not reproducing its legal analysis.
